NCT07236190招募中2 期
Early-phase Biomarker-based Trial of NPC-1 for Alzheimer's Disease Pathology
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Safety and Tolerability of NPC1
研究概览
简要总结
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
Analytical chemists running the biomarker analyses are blind to whether participants are in the lead in or active phase of the intervention
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 55 and older, male and female;
- •Subjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011 criteria;
- •Clinical Dementia Rating < or = to 2 and Mini Mental Status Exam > or = to 16;
- •Modified Hachinski Ischemic Score < or = to 4
- •Geriatric Depression Scale - 15 < 6 documenting absence from significant depressive syndromes
- •Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable > or = to 3-months ;
- •Biomarker evidence of AD pathology: Plasma abeta42/40 ratio < or = to 0.12 AND Plasma p-tau217 > or = to 0.25 OR Amyloid PET positive (centiloid > or = to 20) as part of routine clinical care.
- •Sufficient vision and hearing to complete all tests
- •Study partner available with frequent (at least 1 hour/day or 1 day/week) contact with participant to provide collateral information about cognition, daily functioning, adverse events reporting, and support for study drug intake
- •General health status that will not interfere with the ability to complete the prospective study (these conditions are listed below in the study exclusion list)
排除标准
- •CDR > 2 MMSE < 16;
- •Significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke);
- •Alcohol or substance abuse according to DSM-IV criteria within the last 2 years
- •Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria
- •Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable)
- •Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest)
- •Hypertension: defined as uncontrolled BP > 160/100
- •Clinical symptomatic orthostatic hypotension
- •Diabetes mellitus that requires insulin injections
- •Hachinski ischemic score > or = to 4
- •Cancer within the last 5 years, apart from localized prostate cancer (Gleason Grade < 3) and non-metastatic skin cancers (melanoma).
- •Illness that requires >1 visit /month to a clinician
- •Medications and dietary supplements:
- •a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab
- •b. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollment is permitted)
- •c. CNS active meds that have not been on stable doses for at least 2 months e.g., cimetidine, beta-blockers, and SSRIs
- •d. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit
- •e. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded
- •Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator
- •Currently pregnant. Positive pregnancy tests during the course of the trial will be evaluated at the discretion of the investigator.
- •Women of Child Bearing Potential (WOCBP)
- •For the purposes of this study, women of childbearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria:
- •12-months post-menopausal
- •Post-hysterectomy/surgically sterile
- •If a female Participant does not meet either of these criteria they will be considered of childbearing potential and will have a serum pregnancy test performed at Screening, Visit 3 (2 months), Visit 6 (5 months), and Visit 10 (8 months).
研究组 & 干预措施
Lead-in observational period
No Intervention
Serial blood-based biomarker collection
Active interventional period
Active Comparator
Serial post treatment blood-based biomarkers
干预措施: natural product combination-1 (NPC1) (Combination Product)
结局指标
主要结局
Safety and Tolerability of NPC1
时间窗: Baseline through 6 months
Assessment of Adverse Events Related to NPC1 Treatment
plasma p-tau217
时间窗: 6 months
Intra-individual changes from pre-treatment observational period to post-treatment interventional period
plasma glial fibrillary acidic protein
时间窗: 6 months
Intraindividual changes
plasma neurofilament light chain
时间窗: 6 months
Intra-individual changes
plasma abeta42 / abeta40
时间窗: 6 months
Intraindividual changes
次要结局
- plasma hsTNFalpha(6 months)
研究者
Gene L. Bowman, ND, MPH
Director of Clinical Trials
Massachusetts General Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Japanese Bridging Study of Ivosidenib (AG-120) in Healthy SubjectsHealthyNCT03071770Agios Pharmaceuticals, Inc.60
已完成
1 期
A Study of ZN-c5 in Participants With Breast CancerBreast CancerNCT04176757Zeno Alpha Inc.35
已完成
1 期
A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia MajorBeta-Thalassemia MajorNCT06291961CorrectSequence Therapeutics Co., Ltd9
已完成
1 期
A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy SubjectsHealthy Adult MaleNCT07185113GEn1E Lifesciences6
已完成
1 期
The Effect of Reduced Liver Function on Selatogrel PharmacokineticsHealthy SubjectsHepatic ImpairmentNCT04406896Viatris Innovation GmbH24